List view / Grid view
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
Expectations are growing worldwide for discoveries that will harness the potential of cell therapy, which has already brought breakthroughs in therapeutic areas where there is an unmet need, from oncology to ophthalmology and rare disease. In this article, Dr Terri Gaskell, Chief Technology Officer at Rinri Therapeutics, explores some of…
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
In this article, Dr Mary Spellman, Chief Medical Officer and Senior Vice President of R&D at Castle Creek Biosciences, discusses how a versatile dual platform of ex vivo and in vivo gene therapy technologies is being utilised for the development of novel gene therapies for a broad range of rare…
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
This ebook includes a piece by Daniel Morales- Mantilla, Dr Robin Parihar and Dr Katherine King, from Baylor College of Medicine, on a stem and progenitor cell infusion to improve the survival of mice from sepsis as well as an article by Dr Karen Litwa, East Carolina University, that explores…
In this section, Dr Peter O’Toole, University of York, examines innovation in the field of microscopy for drug discovery and development research, while in an exclusive Q&A, Dr Michael Grange, Rosalind Franklin Institute, discusses the advantages of utilising cryo-electron tomography imaging.
This ebook features insights into the discovery of a new non-linear chiroptical effect for characterising nanohelices in miniscule volumes, and a novel organoid drug-screening platform with numerous eco benefits.
This ebook features articles from gene therapy specialists that look at current platforms as well as the future of promising modalities for gene therapies. It also tackles novel stem cell technology considerations and gives insight into the careful balancing act between efficacy and safety in gene therapy.
In this issue are articles focusing on a novel stem cell therapy for hearing loss, how a non-linear chiroptical effect could aid drug discovery and the advantages of cryo-electron tomography for imaging research. Also included are pieces on gene therapy, spheroids and genomics.
Dr Owen Seddon, University Hospital of Wales, looks at how lessons learned during the pandemic can inform pre-clinical and early R&D phases of future vaccine work.
In this article, Drug Target Review’s Ria Kakkad explores the importance of diverse and inclusive samples in genomic studies with Assistant Professor Lindsay Fernández-Rhodes, Pennsylvania State University.
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
Drug Target Review's Editor Victoria Rees brings you the highlights from the American Association for Cancer Research Meeting 2022.
Looking at disease through a patient’s memory B cells can reveal vulnerabilities within pathogens. In this article, Dr Purnanand Sarma, President and Chief Executive Officer of Immunome, explores how advancements in memory B-cell antibody-based treatments will improve our understanding of how these cells can aid in fighting cancer and other diseases.
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
